Endocrine Abstracts

Background: Nivolumab is a programmed death receptor-1 blocking antibody and the first to gain regulatory approval for use in non-small cell lung cancer (NSCLC). Whilst well tolerated in clinical trials, 3% of patients in a phase Ib study displayed thyroid dysfunction. Diagnosis and referral to appropriate specialties is a challenge in complex cancer cases where symptoms are often multi-factorial. Improved knowledge of the potential complications of new and novel...

Background: Nivolumab is a programmed death receptor-1 blocking antibody and the first to gain regulatory approval for use in non-small cell lung cancer (NSCLC). Whilst well tolerated in clinical trials, 3% of patients in a phase Ib study displayed thyroid dysfunction. Diagnosis and referral to appropriate specialties is a challenge in complex cancer cases where symptoms are often multi-factorial. Improved knowledge of the potential complications of new and novel...